Part 1: General Information		
YODA Project (Protocol) ID:	2019-4035	
Date:	25 October 2019	
Product Name: Canagliflozin		
Therapeutic Area: Metabolism		
Product Class: SGLT-2 inhibitor		
Condition(s) Studied:	Type 2 Diabetes	
Protocol Number(s) and Title(s):	NCT01032629 - 28431754DIA3008 A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ- 28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus NCT01989754 - 28431754DIA4003 A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus	
	Part 2: Data Availability	
	Question:	Response:
Data Holder has authority to provide clinical trial data or development		Yes
partner has agreed to share cli	nical trial data.	
Comments: N/A		
Data Holder has sharable electronic clinical trial data or data can be converted		Yes
to electronic format. Comments: N/A		
De-identification and redaction of clinical trial data in accordance with current		Yes
	rotection of participant privacy and	
confidentiality. Comments: N/A		
1	ation studied has either been approved by	Yes
regulators in the US and EU, or terminated from development.		105
Comments: N/A		
Data Holder has completed the clinical trial and trial has been completed for a		Yes
period of at least 18 months (or results published in peer-reviewed		
biomedical literature).		
Comments: N/A		
P	art 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.		Yes
	Part 4: Proposal Review	
Question:		Response:
Summary-level CSR data is appropriate for the proposed analysis.		No
Participant-level data is appropriate for the proposed analysis.		Yes
A similar analysis is underway Comments:	or completed/pending disclosure by Janssen.	No